Biodesix, Inc. (BDSX) Income Statement
BDSX 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsBDSX revenue and net income
Where BDSX's revenue goes
2025Each bar shows an amount and its share of revenue. BDSX kept −39.8% of revenue as net income.
BDSX profit margins
BDSX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +24.1% | +32.3% | +14.2% | — |
| Gross profit | +28.8% | +44.0% | +25.0% | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
BDSX quarterly EPS vs estimates
Biodesix beat the analyst EPS estimate in 6 of the last 8 quarters. Next report: November 2, 2026 (estimate $-0.74).
BDSX income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $88.5M | $71.3M | $49.1M | $38.2M | $54.5M | $45.6M | $24.6M | $20.4M |
| Cost of revenue | $16.7M | $15.6M | $13.0M | $14.2M | $30.5M | $22.0M | $6.1M | $4.4M |
| Gross profit | $71.8M | $55.8M | $36.1M | $24.1M | $24.0M | $23.6M | $18.5M | $16.0M |
| Research & development | $12.0M | $9.6M | $10.0M | $13.1M | $12.8M | $10.8M | $10.5M | $8.2M |
| Sales, general & admin | $87.5M | $80.5M | $67.8M | $61.5M | $50.5M | $34.9M | $30.6M | $25.9M |
| Total operating expenses | $99.5M | $90.2M | $77.4M | $74.6M | $64.9M | $46.5M | $45.2M | $34.1M |
| Operating income | −$27.8M | −$34.5M | −$41.3M | −$50.6M | −$40.9M | −$22.9M | −$26.7M | −$23.5M |
| Interest income | — | — | — | — | — | $18,000 | $55,000 | $24,000 |
| Interest expense | $7.7M | $8.3M | $9.5M | $8.1M | $4.5M | $7.6M | $3.0M | $2.9M |
| Income before taxes | −$35.3M | −$42.9M | −$52.1M | −$65.4M | −$43.2M | −$31.4M | −$30.7M | −$26.2M |
| Income taxes | — | — | $5.3M | $14.9M | $1.3M | $5.1M | $629,000 | $211,000 |
| Net income | −$35.3M | −$42.9M | −$52.1M | −$65.4M | −$43.2M | −$31.4M | −$30.7M | −$26.2M |
| EBITDA | −$21.9M | −$29.2M | −$37.1M | −$51.5M | −$35.5M | −$20.8M | −$24.9M | −$21.5M |
| EPS (diluted) | −$3.33 | −$5.86 | −$6.54 | −$31.80 | −$22.09 | −$7.12 | −$23.15 | −$1.00 |
| Gross margin | 81.1% | 78.2% | 73.5% | 63.0% | 44.0% | 51.7% | 75.3% | 78.4% |
| Operating margin | −31.4% | −48.4% | −84.2% | −132.4% | −75.1% | −50.3% | −108.9% | −114.8% |
| Net margin | −39.8% | −60.2% | −106.2% | −171.3% | −79.2% | −68.8% | −125.1% | −128.1% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $26.9M | $25.6M | $28.8M | $21.8M | $20.0M | $18.0M | $20.4M | $18.2M | $17.9M | $14.8M | $14.7M | $13.5M |
| Cost of revenue | $4.8M | $4.2M | $4.9M | $4.1M | $4.0M | $3.7M | $4.3M | $4.2M | $3.9M | $3.2M | $3.4M | $3.2M |
| Gross profit | $22.0M | $21.4M | $23.9M | $17.7M | $16.0M | $14.3M | $16.1M | $14.0M | $14.0M | $11.6M | $11.3M | $10.3M |
| Research & development | $3.1M | $3.3M | $2.9M | $3.0M | $3.3M | $2.9M | $2.4M | $2.5M | $2.6M | $2.0M | $1.9M | $1.9M |
| Sales, general & admin | $24.3M | $24.3M | $23.0M | $21.7M | $22.4M | $20.4M | $20.2M | $20.0M | $19.7M | $20.6M | $35.2M | $15.5M |
| Total operating expenses | $27.4M | $27.5M | $25.8M | $24.7M | $25.7M | $23.3M | $22.7M | $22.6M | $22.3M | $22.7M | $18.1M | $17.4M |
| Operating income | −$5.4M | −$6.2M | −$2.0M | −$7.0M | −$9.7M | −$9.1M | −$6.6M | −$8.6M | −$8.2M | −$11.0M | −$6.8M | −$7.2M |
| Interest expense | $2.0M | $2.0M | $2.1M | $2.1M | $1.9M | $1.7M | $1.8M | $2.0M | $1.9M | $2.5M | $2.3M | $2.4M |
| Income before taxes | −$7.3M | −$7.8M | −$4.0M | −$8.7M | −$11.5M | −$11.1M | −$8.3M | −$10.3M | −$10.8M | −$13.6M | −$9.1M | −$10.9M |
| Income taxes | — | — | — | — | — | — | −$1.3M | −$1.4M | — | $1.3M | −$3.2M | $2.4M |
| Net income | −$7.3M | −$7.8M | −$4.0M | −$8.7M | −$11.5M | −$11.1M | −$8.3M | −$10.3M | −$10.8M | −$13.6M | −$9.1M | −$10.9M |
| EBITDA | −$4.1M | −$4.4M | −$515,000 | −$5.3M | −$8.2M | −$8.0M | −$5.1M | −$6.8M | −$7.6M | −$9.8M | −$5.5M | −$7.3M |
| EPS (diluted) | −$0.71 | −$0.81 | −$0.49 | −$1.16 | −$0.08 | −$1.60 | −$0.06 | −$1.40 | −$1.60 | −$2.80 | −$0.10 | −$2.80 |
| Gross margin | 82.1% | 83.5% | 83.0% | 81.1% | 79.9% | 79.4% | 78.7% | 77.0% | 78.4% | 78.6% | 77.0% | 76.1% |
| Operating margin | −20.1% | −24.2% | −6.8% | −32.4% | −48.4% | −50.5% | −32.5% | −47.3% | −46.0% | −74.4% | −46.7% | −53.2% |
| Net margin | −27.1% | −30.5% | −13.8% | −40.0% | −57.3% | −61.8% | −40.4% | −56.5% | −60.3% | −91.9% | −62.3% | −81.2% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in BDSX's financial statements (latest annual report filed February 26, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
BDSX financial results
In fiscal year 2025 (ended December 31, 2025), Biodesix reported revenue of $88.5 million, up 24.1% from the year before. It had a net loss of $35.3 million, a net profit margin of −39.8%. Diluted earnings per share came to −$3.33. Over five years revenue grew at an average rate of 14.2% a year.
See the BDSX stock overview for the latest quote and news, or the BDSX chart for price history and technical indicators.
BDSX income statement FAQ
What is Biodesix's annual revenue?
Biodesix reported total revenue of $88.5 million for fiscal year 2025, which ended on December 31, 2025. That was up 24.1% from $71.3 million the previous year.
Is Biodesix profitable?
No. Biodesix reported a net loss of $35.3 million in fiscal 2025, a net profit margin of −39.8%; its operating margin was −31.4%.
What is Biodesix's gross margin?
Biodesix's gross margin was 81.1% in fiscal 2025: for every $100 of revenue, Biodesix kept $81 after the direct cost of its products and services.
How much does Biodesix spend on research and development?
Biodesix spent $12.0 million on research and development in fiscal 2025, 13.6% of revenue.
How fast is Biodesix growing?
Revenue grew 14.2% a year on average over the last five fiscal years, from $45.6 million to $88.5 million.
What are Biodesix's earnings per share?
Biodesix earned $-3.33 per diluted share in fiscal 2025, compared with $-5.86 a year earlier.
When will Biodesix report its next earnings?
Biodesix is expected to report results for the quarter ending September 30, 2026 on November 2, 2026.
When does Biodesix's fiscal year end?
Biodesix's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 26, 2026.